Share Price* Market Cap*

$1.03 $29.5M
D I A G N O S TI C S 52-Week Range* Net Revenue Est.†

$0.77-1.78 $21 - 22M *as of 11/26/18

Overview
Interpace Diagnostics is a fully integrated commercial and and treatment options. The Company has nationwide
bioinformatics company that provides clinically useful molecular reimbursement for its products with major healthcare
and related first line diagnostic tests and pathology services for providers like United Healthcare, Cigna, Medicare,
evaluating risk of cancer by leveraging the latest technology in Aetna, Blue Cross Blue Shield and more.
personalized medicine for improved patient diagnosis and
management. Interpace’s unique molecular tests offer healthcare
COVERED BY 30
providers and patients the benefit of early cancer detection and
REGIONAL
prognostic evaluation and accordingly more selective surgical
BLUE
CROSS BLUE
SHIELD PLANS

Thyroid Products
ThyGenX ® /ThyGeNEXT™ and ThyraMIR ® When used in combination,

ThyGenX® - Thyroid Oncogene Panel 85% ThyGenX®/ThyGeNEXT™ and ThyraMIR®

offer a 94% NPV, a 74% PPV, and an 85%
Highly specific oncogene (mutational) panel that reduction in
assesses the most common genetic alternations unnecessary reduction in unnecessary surgeries.
across 8 genes associated with both papillary surgeries
Sensitivity is 89% and Specificity is 85%
carcinoma and follicular carcinoma.

ThyGeNEXT™ - Next Generation Mutation Panel

Goes above and beyond ThyGenX® to include
numerous additional molecular markers, gene
275 Interpace’s thyroid tests cover over
million lives 275 million lives
mutations, and RNA fusions. This more covered
comprehensive set of indicators not only
identifies malignant and malign nodules, but also
ascertains aggressiveness and other
characteristics.
20K Over 20,000 molecular thyroid tests
performed by over 400 physicians and
thyroid tests
ThyraMIR® - Thyroid miRNA Classifier conducted hospitals nationwide
The first and only miRNA gene expression classifier
and is based on the evaluation of the relative
expression of 10 miRNAs.
 PancraGEN ® 55,440 80% >30,000
PancraGEN® is a unique, DNA-based integrated molecular
estimated new of surgeries tests performed
cases of pancreatic reveal idolent
pathology test that assesses the risk of pancreatic and bileduct
cancer in 2018 cysts, which don't
cancer in pancreatic cysts and pancreaticobiliary solid lesions.
require surgery
It is the first and only U.S. commercially available molecular
test for pancreatic cancer evaluation. PancraGEN® has better predictive value for cancer than guidelines
and identifies more patients in whom surgery can be avoided

234,030 $13.4 billion RespriDx™

RespriDx™ is a test to determine whether abnormal
estimated new cases of cost of lung cancer care growths represent metastases or new primary lung
lung cancer in 2018 in the U.S. in 2015 cancers.

BarreGEN® ~3.5 million

BarreGEN® enables the assessment for the risk of progression $1 – $1.5 billion adults in the U.S. will be
from Barrett’s Esophagus, a rapidly growing condition, to market potential in the U.S. diagnosed with
esophageal cancer, allowing for more personalized Barrett’s Esophagus
management of the disease.

Gross profit
Revenue for 2017 was
Financials percentage for 2017
improved to 53.7%,
Cash & cash equivalents
on hand at $15.9M representing a
09/30/2018:$8.0M with 21% increase
compared to 49.2%
no long-term debt compared to 2016
in 2016

Revenue guidance Adjusted EBITDA was

increased for 2018 Q2 2018 record Stockholder's Equity $(3.4) million for the
from $20 million to quarterly revenue of amounted to $36.0 nine-month period
range between $5.5 million million as of 09/30/18 ended on 9/30/18
$21 - $22 million

Managment Contact
Jack Stover – Chief Executive Officer Edison Advisors
Greg Richard – Chief Commercial Officer Joe Green/Andrew Gibson
Syd Finkelstein, MD – Chief Scientific Officer
(646) 653-7030/(646) 653-7719
Alidad Mireskandari, PhD – VP of Business Development
jgreen@edisongroup.com
Jim Early – Chief Financial Officer
Sara A. Jackson, PhD – VP of Clinical Development agibson@edisongroup.com
Glenn Gershon – SVP of Operations
Christina Narick, MD – VP of Pathology